Cargando…

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gowen, Michael F., Giles, Keith M., Simpson, Danny, Tchack, Jeremy, Zhou, Hua, Moran, Una, Dawood, Zarmeena, Pavlick, Anna C., Hu, Shaohui, Wilson, Melissa A., Zhong, Hua, Krogsgaard, Michelle, Kirchhoff, Tomas, Osman, Iman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880088/ https://www.ncbi.nlm.nih.gov/pubmed/29606147 http://dx.doi.org/10.1186/s12967-018-1452-4

Ejemplares similares

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)
por: Ferguson, Robert, et al.
Publicado: (2019)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
por: Usyk, Mykhaylo, et al.
Publicado: (2021)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
por: Lattanzi, Michael, et al.
Publicado: (2018)

Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
por: Weiss, Sarah A., et al.
Publicado: (2016)

A genome-wide association study of germline variation and melanoma prognosis
por: Chat, Vylyny, et al.
Publicado: (2023)

2081: Phenotypic characterization of the CD4+ T-cell response during anti-CTLA4 therapy with ipilimumab in melanoma patients
por: Sherani, Farha, et al.
Publicado: (2018)

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
por: Peters, Brandilyn A., et al.
Publicado: (2019)

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2021)

Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
por: Weiss, Sarah, et al.
Publicado: (2015)

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
por: Donnelly, Douglas, et al.
Publicado: (2019)

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2020)

Melanoma risk loci as determinants of melanoma recurrence and survival
por: Rendleman, Justin, et al.
Publicado: (2013)

Tumor immunogenomic signatures improve a prognostic model of melanoma survival
por: Morales, Leah, et al.
Publicado: (2021)

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
por: Finger, Paul T., et al.
Publicado: (2019)

Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma
por: Chou, Margaret, et al.
Publicado: (2020)

Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy
por: Moogk, Duane, et al.
Publicado: (2014)

Correction: Tumor immunogenomic signatures improve a prognostic model of melanoma survival
por: Morales, Leah, et al.
Publicado: (2023)

Deletion of PTENP1 pseudogene in human melanoma
por: Poliseno, Laura, et al.
Publicado: (2011)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo
por: O’Reilly, Kathryn E., et al.
Publicado: (2013)

The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma
por: Huynh, Chanh, et al.
Publicado: (2011)

Serum microRNAs as biomarkers for recurrence in melanoma
por: Friedman, Erica B, et al.
Publicado: (2012)

Correction: The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma
por: Huynh, Chanh, et al.
Publicado: (2011)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

MLTI-03. FIRST-LINE STEREOTACTIC RADIOSURGERY COMBINED WITH SYSTEMIC TARGETED AND IMMUNE CHECKPOINT INHIBITOR THERAPY IN MELANOMA PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
por: Heumann, Thatcher, et al.
Publicado: (2019)

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
por: Ott, Patrick A., et al.
Publicado: (2010)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic
por: Osman, Iman, et al.
Publicado: (2020)

Correction to: The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic
por: Osman, Iman, et al.
Publicado: (2021)

Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
por: Lomax, Anna J., et al.
Publicado: (2018)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
por: Taylor, Chelsea A., et al.
Publicado: (2022)

Genetic markers of pigmentation are novel risk loci for uveal melanoma
por: Ferguson, Robert, et al.
Publicado: (2016)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
por: Jang, Se Ryeong, et al.
Publicado: (2021)

Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma
por: Velazquez, Elsa F, et al.
Publicado: (2007)

Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients
por: Rosenbaum, Brooke E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nji53lugpr0iv09dfaet8ika18